LUM and congenital bilateral aplasia of vas deferens from CFTR mutation: Huang et al. demonstrated that lumican mediates H3K14la and H3K9la, thereby promoting aortic valve calcification and suggesting that lumican could be a potential therapeutic target for calcific aortic valve disease (CAVD) 191.